Craig Perry & Erez Kalir's Sabretooth Capital Trim Pain Therapeutics (PTIE) Stake ~ market folly

Wednesday, October 5, 2011

Craig Perry & Erez Kalir's Sabretooth Capital Trim Pain Therapeutics (PTIE) Stake

Craig Perry and Erez Kalir's hedge fund Sabretooth Capital just filed a Form 4 with the SEC regarding shares of Pain Therapeutics (PTIE). Per the filing, they disclose that they sold 382,000 shares of PTIE on October 3rd & 4th, with the bulk of the sale coming at a price of $4.5025.

After their sales, Sabretooth still owns 4,263,076 shares of Pain Therapeutics. As such, they've only reduced their position by around 8%. Shares of PTIE currently trade around $4.40.

Sabretooth Capital Background

Perry and Kalir co-founded Sabretooth Capital in March 2009 with $65 million in seed money from Tiger Management's Julian Robertson. As of mid-2011, they had raised around $700 million. Sabretooth returned 26.5% in 2009 and just over 14% for 2010.

In the past we've covered Erez Kalir's presentation on MBIA (MBI) from the Ira Sohn Conference. Sabretooth is a multi-strategy firm and starts by analyzing top down macro trends and then selects individual securities from bottom-up fundamental analysis.

Prior to founding their firm, Perry was a distressed debt analyst for King Street Capital and earned his economics degree from Princeton. Kalir previously worked at Eton Park Capital and earned an MSc in biology from the University of Oxford and a degree in literature from Stanford University.

Both Perry and Kalir were featured in Institutional Investor's "2011 hedge fund rising stars." And according to II, they named their fund Sabretooth after an extinct animal because they wanted to imitate the 'dinosaurs' of the hedge fund industry (like Robertson) who returned greater than 20% annualized.

Pain Therapeutics Company Background

Per Google Finance, Pain Therapeutics is "a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. It has collaboration agreement with King Pharmaceuticals, Inc. (King) develops and commercializes REMOXY and other opioid painkillers."

blog comments powered by Disqus